Wall Street urged Pfizer to lower its COVID revenue estimates. The company did — but it’s still betting on higher demand for its vaccine and antiviral by 2025.
You are here: Home / Top Stories / : Pfizer’s COVID revenues have dropped off along with attention to the pandemic